A special, discounted room rate is available for early registrants of the second MidWest Drug Development Conference.
The second MidWest Drug Development Conference will feature around 16 institutions from 12 states, condensing an area of 780,000 square miles into one location.
OMAHA, Neb. (May, 15, 2019)—The MidWest Drug Development Conference will enter its second year, and registrations are now open.
The event will feature the top therapeutic technologies from more than a dozen Midwestern medical research universities and institutions, including Mayo Clinic, the University of Wisconsin’s WARF, Colorado, Missouri, Nebraska and Notre Dame, to name a few.
OMAHA, Nebraska (January 30, 2019)—Due to the overall success and popularity of the inaugural MidWest Drug Development Conference last year, the event will return for a second year and registrations are now open, planners announced today.
The conference will again span two days, featuring Midwestern university technologies, beginning on Monday, Sept. 31, and concluding the following day, Tuesday, Oct. 1. The same venue—the Capital District Marriott in downtown Omaha—will house the event.
OMAHA, Nebraska (December 11, 2018)—The final results are in, and the inaugural MidWest Drug Development Conference was an unqualified success, UNeMed announced today.
“No question about it,” said Michael Dixon, CEO and President at UNeMed, the event’s primary host. “Taking a swing at something major like this is more than a little nerve-wracking. Will anyone show up? Are we wasting our time? But this was a home run, no doubt—and not just for us.”
As the first-ever Midwest Drug Development Conference winds down, please take a moment to help us learn where we went wrong, where we went right and how to improve the event for next year, or even if the event is worth repeating. It’s only 10 questions and should only take about four minutes.
It’s last call for presentations at the Midwest Drug Development conference, officials announced today.
Only 10 slots remain open in the two-day slate of early- and mid-stage technologies that will be presented to guests from the worlds of biomedical therapeutics and investor groups.